Nanobiotix Secures $71 Million in Non-Dilutive Financing
Nanobiotix has finalized a non-dilutive royalty sharing financing agreement with Healthcare Royalty, securing an initial $50 million cash inflow.
Details of the Financing Agreement
According to a press release from Nanobiotix, the company has completed a non-dilutive royalty sharing financing agreement with Healthcare Royalty. This partnership enabled Nanobiotix to receive an initial payment of $50 million, with an additional $21 million expected within a year, contingent upon meeting certain conditions. Healthcare Royalty will receive payments linked to the sales of JNJ-1900 (NBTXR3) and the achievement of specific regulatory and commercial milestones.
Progress in Product Development
Nanobiotix continues to advance its product JNJ-1900 (NBTXR3), with new Phase 1 data in esophageal cancer presented at ASTRO. The transfer of the Phase 3 study sponsorship for head and neck cancers to Johnson & Johnson has been completed, strengthening the collaboration between the two entities. Additionally, studies on various tumors conducted by Nanobiotix and the MD Anderson Cancer Center are expected to provide new data by 2026.
Financial Outlook and Future Plans
As of September 30, 2025, Nanobiotix had €20.4 million in cash and cash equivalents. The agreement with Healthcare Royalty is expected to extend the company's cash runway until early 2028, thanks to the anticipated $71 million. The company plans to continue its clinical developments and collaborations for JNJ-1900 (NBTXR3), including ongoing studies in the United States.
